Last reviewed · How we verify

Clovis Oncology, Inc. — Portfolio Competitive Intelligence Brief

Clovis Oncology, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
MPDL3280A MPDL3280A phase 3 PD-L1 inhibitor PD-L1 Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 2 shared drug classes
  2. AbbVie (prior sponsor, Abbott) · 1 shared drug class
  3. Ascletis Pharmaceuticals Co., Ltd. · 1 shared drug class
  4. Assistance Publique Hopitaux De Marseille · 1 shared drug class
  5. AbbVie · 1 shared drug class
  6. BeiGene · 1 shared drug class
  7. Biocad · 1 shared drug class
  8. 3D Medicines (Sichuan) Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Clovis Oncology, Inc.:

Cite this brief

Drug Landscape (2026). Clovis Oncology, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/clovis-oncology-inc. Accessed 2026-05-14.

Related